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Objectives: Little is known about platelet transfusions in pediatric 
critical illness. We sought to describe the epidemiology, indica-
tions, and outcomes of platelet transfusions among critically ill 
children.
Design: Prospective cohort study.
Setting: Multicenter (82 PICUs), international (16 countries) from 
September 2016 to April 2017.
Patients: Children ages 3 days to 16 years prescribed a platelet 
transfusion in the ICU during screening days.
Interventions: None.
Measurements and Main Results: Over 6 weeks, 16,934 patients 
were eligible, and 559 received at least one platelet transfusion 
(prevalence, 3.3%). The indications for transfusion included pro-
phylaxis (67%), minor bleeding (21%), and major bleeding (12%). 
Thirty-four percent of prophylactic platelet transfusions were 
prescribed when the platelet count was greater than or equal 
to 50 × 109 cells/L. The median (interquartile range) change in 
platelet count post transfusion was 48 × 109 cells/L (17–82 × 109 
cells/L) for major bleeding, 42 × 109 cells/L (16–80 × 109 cells/L) 
for prophylactic transfusions to meet a defined threshold, 38 × 109 
cells/L (17–72 × 109 cells/L) for minor bleeding, and 25 × 109 
cells/L (10–47 × 109 cells/L) for prophylaxis in patients at risk of 
bleeding from a device. Overall ICU mortality was 25% but var-
ied from 18% to 35% based on indication for transfusion. Upon 
adjusted analysis, total administered platelet dose was indepen-
dently associated with increased ICU mortality (odds ratio for 
each additional 1 mL/kg platelets transfused, 1.002; 95% CI, 
1.001–1.003; p = 0.005).
Conclusions: The majority of platelet transfusions are given as 
prophylaxis to nonbleeding children, and significant variation in 
platelet thresholds exists. Studies are needed to clarify appropri-
ate indications, with focus on prophylactic transfusions. (Crit Care 
Med 2018; 46:1309–1317)
Key Words: critical care; pediatrics; platelet transfusions; 
thrombocytopenia 
Platelet transfusions are commonly prescribed in critical illness, but uncertainty remains regarding their efficacy and safety for all indications. In 2015, an American Asso-
ciation of Blood Banks (AABB) survey reported that 48,000 
children in the United States received 165,000 apheresis plate-
let units (1). Unfortunately, there is no information regarding DOI: 10.1097/CCM.0000000000003192
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the epidemiology, indications, and outcomes for critically ill 
children receiving platelet transfusions.
Evidence-based guidelines for pediatric platelet transfu-
sions are generally lacking and based primarily on expert 
opinion. Recommendations published by the AABB state that 
pediatric platelet transfusions are indicated for 1) total platelet 
count (TPC) less than 10 × 109 cells/L due to hypoproliferative 
thrombocytopenia, 2) active bleeding in association with qual-
itative platelet defects, 3) unexplained excessive bleeding when 
undergoing cardiopulmonary bypass, or 4) patients undergo-
ing extracorporeal membrane oxygenation (ECMO) with TPC 
less than 100 × 109 cells/L (2).
Little is known about the practice of platelet transfusion 
in pediatric critical illness. In order to evaluate platelet trans-
fusion strategies in critically ill children and guide platelet 
transfusion practices, it is important to understand the epide-
miology. The primary objective of the study was to describe 
patterns of platelet transfusions among critically ill children, 
including transfusion thresholds, indications, posttransfusion 
platelet count increment, and outcomes. The international 
nature supports its generalizability.
METHODS
Study Population
This point prevalence study was an exploratory, international, 
prospective, cross-sectional design. PICUs were recruited 
through the Pediatric Critical Care Blood Research Network, 
Pediatric Acute Lung Injury and Sepsis Investigators network, 
several international critical care societies, and sites who previ-
ously participated in an epidemiologic study of plasma trans-
fusions (3). Sites were encouraged to recruit across all pediatric 
critical care areas, including specialized pediatric cardiac criti-
cal care units, but were not required to do so. Each site was 
assigned 6 random weeks (between September 2016 and April 
2017) and screened all 7 days of each week. A child was con-
sidered eligible if admitted to the PICU during one of the 
screening days and between 3 days and 16 years old. A potential 
subject was enrolled if he/she received a platelet transfusion 
prescribed by the intensive care team during one of the screen-
ing days. Patients were excluded if life expectancy was less than 
24 hours, gestational age was less than 37 weeks, or the patient 
was previously enrolled. The study was approved by the Insti-
tutional Review Board at each site, except for the United King-
dom where it was approved by the Health Research Authority 
of the National Health Service. Waiver of consent was granted 
at all sites except one in Italy that required written consent. 
Sites in Switzerland required a description of the study to be 
posted with an opt-out possibility for families.
Data Collection
For each enrolled subject, the site chose from the follow-
ing indications for the transfusion (more than one could 
be selected): 1) TPC less than 10 × 109 cells/L with failure of 
platelet production; 2) TPC less than 30 × 109 cells/L in neo-
nate with failure of platelet production; 3) major bleeding as 
defined by a) bleeding requiring massive transfusion; b) intra-
cranial, intraocular, retroperitoneal, intraspinal, or nontrau-
matic intra-articular bleeding; or c) bleeding requiring surgical 
intervention (i.e., hemothorax requiring drainage); 4) minor 
bleeding (surgical or nonsurgical) as defined by any bleed-
ing not meeting criteria for major bleeding; 5) preparation 
for surgery; 6) preparation for invasive procedure; 7) known 
qualitative platelet defect with risk of bleeding; or 8) at risk 
of bleeding from device. Indications 1, 2, 5, 6, 7, and 8 were 
all categorized as “prophylactic” transfusions. When sites were 
unsure of indication, the record was reviewed by the study 
principal investigator (PI), and an assignment was made after 
discussion with the local PI.
Data collected included patient demographics, reason for 
admission, any prior platelet transfusions, attributes of the 
platelet product (dose, source, and processing), any adverse 
reactions to the transfusion, and laboratory assays assessed 
before and after transfusion. All laboratory data were col-
lected at the discretion of the medical team and recorded by 
the research team up to 24 hours prior to and 36 hours fol-
lowing the transfusion of interest. Major clinical outcome 
data, including length of stay, length of mechanical ventilation, 
mortality, and degree of organ dysfunction, as measured by 
PELOD-2 score (4) were collected. Study data were managed 
using Research Electronic Data Capture electronic data cap-
ture tools hosted at Weill Cornell Medicine.
Statistical Approach
Demographic and clinical characteristics were described as n 
(%) or mean ± sd or median and interquartile range (IQR), 
as appropriate. Categorical data were compared by Fisher 
exact/chi-square tests. Continuous variables were compared 
by analysis of variance/Kruskal-Wallis tests or t test/Wilcoxon 
Rank-Sum for parametric/nonparametric data, respectively. 
All p values were two sided with statistical significance evalu-
ated at the 0.05 alpha level. All analyses for descriptive statistics 
were performed in R version 3.4.0 (R Foundation for Statistical 
Computing, Vienna, Austria).
To assess the independent association between total admin-
istered platelet dose and mortality, a multivariable logistic 
regression model was developed. Candidate variables with a p 
value of less than 0.1 on unadjusted analyses were included. 
These were full days since PICU admission, ECMO, PELOD-2 
score on day of transfusion, bleeding as indication for trans-
fusion, postoperative status at admission to PICU, and lowest 
platelet count on day of admission. Multicollinearity between 
variables was assessed and determined not to be an issue. The 
regression was performed using a backward, stepwise model. 
All analyses for outcomes data were conducted using SPSS ver-
sion 25 (IBM Corp, Armonk, NY).
RESULTS
Prevalence
Eighty-two sites from 16 countries participated. The majority 
of sites were urban (97%), academic (98%), trauma centers 
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(85%), and ECMO centers (80%). Of the participating sites, 
48 of 82 (58%) were located in North America, 23 of 82 (28%) 
in Europe, four of 82 (5%) in Oceania, four of 82 (5%) in the 
Middle East, and three of 82 (4%) in Asia.
During the 6 weeks of screening, 16,934 patients were eli-
gible. Of those, 559 received platelet transfusions and were 
enrolled yielding a platelet transfusion prevalence of 3.3% per 
patient. There were nine of 82 sites (11%) that did not trans-
fuse platelets during the entire study period. The sites that 
did not transfuse any eligible subjects were limited to North 
America and Europe.
Subjects
Subject demographics are summarized in Table 1 and cat-
egorized according to indication for platelet transfusion. The 
median (IQR) age was 4.1 years (0.5–10.8 yr), and 55% were 
male. The three most common reasons for admission were 
respiratory insufficiency/failure (39%), septic shock (22%), 
and cardiac surgery involving bypass (12%). Nearly half the 
subjects (44%) had an underlying oncologic diagnosis. The 
majority were mechanically ventilated at time of transfu-
sion (64.4%) and admitted to the PICU for a median (IQR) 
length of 2 days (2–7 d) before enrollment. The median (IQR) 
TABLE 1. Demographics of Subjects
Variables
Major Bleeding  
(n = 64)
Minor Bleeding  
(n = 115)
Prophylactic Trans-
fusions in Patients 
on Devices (n = 79)
Prophylactic Trans-
fusions to Meet 
Threshold (n = 278) p 
Age (yr), median (IQR) 3 (0–11) 4 (0–10) 0 (0–3) 5 (1–11) < 0.001
Sex (male), n (%) 33 (52) 66 (57) 44 (56) 152 (55) 0.897
Weight (kg), median (IQR) 13.7 (5.9–36.5) 16.0 (8.5- 28.5) 6.4 (3.5–18.8) 19.1 (8.6–38.1) < 0.001
Days since admission, median (IQR) 1 (0–3) 2 (0–8.8) 5 (2–13) 2 (0–6) < 0.001
Mechanical ventilation, n (%) 48 (75) 82 (71) 74 (94) 141 (51) < 0.001
Underlying oncologic diagnosis, n (%) 21 (34) 35 (31) 9 (12) 155 (59) < 0.001
Reason for PICU admission, n (%)      
 Respiratory 15 (23) 51 (44) 48 (61) 96 (35) < 0.001
 Septic shock 4 (6) 22 (19) 9 (11) 85 (31) < 0.001
 Hemorrhagic shock 16 (25) 5 (4) 2 (3) 6 (2) < 0.001
 Other Shock 4 (6) 5 (4) 4 (5) 11 (4) 0.810
 Trauma 4 (6) 7 (6) 1 (1) 2 (1) 0.002
 Traumatic brain injury 3 (5) 2 (2) 0 (0) 3 (1) 0.114
 Burn 0 (0) 1 (1) 0 (0) 1 (0) 0.731
 Cardiac surgery—bypass 14 (22) 17 (15) 13 (16) 21 (8) 0.004
 Cardiac surgery—no bypass 1 (2) 4 (3) 1 (1) 3 (1) 0.366
 Cardiac—nonsurgical 3 (5) 10 (9) 12 (15) 16 (6) 0.047
 Emergency surgery 4 (6) 1 (1) 3 (4) 6 (2) 0.131
 Elective surgery 3 (5) 7 (6) 5 (6) 8 (3) 0.312
 Seizure 1 (2) 6 (5) 0 (0) 8 (3) 0.181
 Encephalopathy 6 (9) 15 (13) 4 (5) 16 (6) 0.078
 Meningitis 0 (0) 1 (1) 2 (3) 2 (1) 0.390
 Renal failure 3 (5) 15 (13) 8 (10) 29 (10) 0.371
 Hepatic failure 3 (5) 8 (7) 2 (3) 13 (5) 0.576
 Postoperative liver transplant 2 (3) 3 (3) 1 (1) 7 (3) 0.879
 Other 23 (36) 27 (23) 15 (19) 92 (33) 0.026
PELOD-2 score prior to transfusion, 
median (IQR)
7 (5.5–10.5) 7 (6–11) 8 (7–11) 7 (4–9) 0.001
IQR = interquartile range.
Of the 559 patients transfused and enrolled, 536 had reported data.
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PELOD-2 score at enrollment was 7 (5–10). The frequency of 
subjects receiving medications that may affect platelet func-
tion was milrinone (17%), aspirin (3%), and nonsteroidal 
anti-inflammatories (2%). Subjects were supported by the fol-
lowing devices at time of platelet transfusion: ECMO (17%), 
continuous renal replacement therapy (CRRT) (11%), inter-
mittent hemodialysis (1%), and molecular adsorbent recircu-
lation system (1%). Approximately one third of the children 
(36%) had received at least one other platelet transfusion in 
the PICU during the admission prior to enrollment.
Indications
The indications for each platelet transfusion are summarized 
in Figure 1. The majority (67%) of transfusions were prophy-
lactic; major or minor bleeding was the indication in only one 
third of transfusions (33%). Of the 79 patients who received 
prophylactic transfusions while on mechanical circulatory 
devices, 67 (85%) were supported by ECMO, and 12 (15%) 
were supported with CRRT.
Blood Product/Transfusion Event
The majority of platelets transfused were collected by apher-
esis (87%) or whole blood derived (13%). The transfusions 
were commonly leukoreduced (93%) and irradiated (80%). 
They were infrequently volume reduced (8%), pathogen inac-
tivated (5%), or human leukocyte antigen matched (1%). 
The median (IQR) administered platelet dose per transfu-
sion event was 9.4 mL/kg (5.5–13.1 mL/kg). Subjects received 
a median (IQR) 4 (2–11) platelet transfusion events during 
their PICU course for a total median (IQR) administered dose 
of 32.4 mL/kg (14.0–91.4 mL/kg). The total number of trans-
fusions that the 559 enrolled subjects received over their PICU 
admissions was 6,090.
Reported adverse reactions 
were uncommon. In the 515 
transfusions in which this data 
were entered, there were a total 
of 32 reactions (6%). A new 
fever or increase in tempera-
ture by 1°C, if already febrile, 
occurred most frequently 
(3%), followed by hypotension 
(3%), urticaria (0.6%), and 
bronchospasm (0.2%). There 
were no hemolytic reactions or 
confirmed septic reactions.
Laboratory Assays
The TPC was known prior to 
transfusion in the vast major-
ity of cases (99%). The median 
(IQR) TPC prior to transfusion 
was 40 × 109 cells/L (20–66 × 109 
cells/L). Thirty-four percent of 
transfusions were prescribed 
when the TPC was greater than 
or equal to 50 × 109 cells/L. Of the 278 prophylactic transfusions 
prescribed to meet a threshold, 46 (17%) were given to surgical 
patients. The median (IQR) TPC prior to transfusion in patients 
with surgical indications for PICU admission was 48 × 109 cells/L 
(30–81 × 109 cells/L). This differed significantly (p < 0.001) from 
medical patients whose median (IQR) TPC prior to transfusion 
was 26 × 109 cells/L (15–42 × 109 cells/L) (Supplemental Fig. 1, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
D564; legend: Comparison of medical and surgical patients 
receiving prophylactic transfusions to meet a defined threshold.).
Viscoelastic testing, such as thromboelastography and rota-
tional thromboelastometry (ROTEM), was uncommonly ana-
lyzed prior to transfusion (5% and 2%, respectively).
Figure 2 depicts the change in TPC following transfusion 
at various times and for various indications corrected for 
transfusion dose. The median change in TPC varied across 
groups based on indication (p = 0.03). For every 10 mL/kg 
of platelets transfused, the median (IQR) change in TPC was 
48 × 109 cells/L (17–82 × 109 cells/L) for patients with major 
bleeding, 42 × 109 cells/L (16–80 × 109 cells/L) for prophylactic 
transfusions to meet a threshold, 38 × 109 cells/L (17–72 × 109 
cells/L) for patients with minor bleeding, and 25 × 109 cells/L 
(10–47 × 109 cells/L) for prophylactic transfusions in patients 
at risk of bleeding from a device. The incremental change in 
TPC did not vary between those who had an underlying onco-
logic diagnosis and those who did not (p = 0.57).
Outcomes
Outcome data were available for 532 of the 559 enrolled 
patients. The median (IQR) length of stay in the PICU was 13 
days (6–29 d). The median (IQR) number of ventilator-free 
days was 4 (1–9). The mortality rate for all children was 25%. 
Outcomes based on indication are summarized in Table 2. 
Figure 1. Indications for platelet transfusions.
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Variables associated with ICU mortality by univariate regres-
sion analysis are described in Supplemental Table 1 (Supple-
mental Digital Content 2, http://links.lww.com/CCM/D565). 
In the unadjusted model, each additional 1 mL/kg of platelets 
transfused was associated with an increase in mortality of 0.3% 
(odds ratio, 1.003; 95% CI, 1.002–1.004; p < 0.001). Multivari-
able logistic regression showed a 2% increase in mortality for 
every additional standard dose (10 mL/kg) of platelets admin-
istered after adjustment for confounding variables (odds ratio 
for each additional 1 mL/kg transfused of 1.002; 95% CI, 
1.001–1.003; p = 0.005), shown in Table 3.
DISCUSSION
This international point prevalence study is the first published 
analysis of the epidemiology, indications, and outcomes of 
critically ill children transfused platelets. Approximately two 
thirds of platelet transfusions were prescribed in a prophylac-
tic manner to nonbleeding children. Thirty-four percent of 
prophylactic transfusions were prescribed when the TPC was 
greater than or equal to 50 × 109 cells/L. Although the observed 
rise in TPC following transfusion varied based on indica-
tion, those at risk of bleeding from a circulatory device had 
the smallest increase. Mortality in patients who receive platelet 
Figure 2. Change in platelet count following transfusion by indication.
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transfusions was high, ranging from 17% to 35% according 
to indication. There was an independent association between 
administered platelet dose and mortality.
Platelet transfusion practices observed in this study resem-
ble those published in adults. In one large observational study 
of critically ill adults in the United Kingdom, wide variation in 
platelet use was reported (5). The prevalence of platelet trans-
fusion was 9%. More than half of platelet units were given as 
“prophylactic transfusions” in patients with no documented 
bleeding. One third of transfusions were given when the TPC 
greater than 50 × 109 cells/L. Similar findings were seen in a ret-
rospective study from three adult ICUs in Canada; the median 
TPC reported prior to platelet transfusion was 87 × 109 cells/L 
(6). In these same two studies, the median (IQR) increment 
in TPC following transfusion was modest, 15 × 109 cells/L (2–
36 × 109 cells/L) and 23 × 109 cells/L (7–44 × 109 cells/L) (5, 6).
Pediatric data from a single-center prospective study 
reported the prevalence of critically ill children receiving at 
least one platelet transfusion to be 7.2% (7). The average 
TPC was 49 ± 34 × 109 cells/L prior to transfusion, similar 
to thresholds reported here. They reported a wide range of 
incremental changes in TPC following transfusion (from 30 
to nearly 100 × 109 cells/L), based on indication for transfu-
sion. The variation in TPC noted in our study is likely not 
only due to differences in the indication for transfusion but 
also due to differences in patient characteristics or etiology of 
thrombocytopenia. For example, change in TPC is expected 
to be different between patients transfused prophylactically 
in preparation for neurosurgery compared with a bleeding 
patient with an oncologic disorder. Of note, the incremental 
change in TPC we report did not vary with the presence or 
absence of an underlying oncologic diagnosis. The incremen-
tal change in TPC in critically ill children following platelet 
transfusion may be higher than that observed in critically 
ill adults because of better ABO compatibility, which was 
implicated in improved posttransfusion platelet increment in 
adults with hematologic malignancies (8). The incremental 
change in TPC we report also varied by indication for trans-
fusion. The smallest incremental change was seen in those at 
risk of bleeding from a device, which may be theoretically 
explained by alloimmunization and consumption related to 
the device itself. Children with major bleeding had a greater 
median rise in TPC than those with minor or no bleed-
ing. Variations in platelet products, including storage solu-
tion, age, and temperature, may have impacted the median 
change in TPC post transfusion. Differences in storage solu-
tion affect posttransfusion platelet count at 1 and 24 hours 
and may have played a role (9, 10). In addition, differences 
in age of the platelets transfused has been related to clini-
cal complications in trauma patients (11). Platelets stored at 
TABLE 2. Outcomes by Diagnosis
Variables
Major Bleeding (n 
= 64)
Minor Bleeding (n 
= 113)
Prophylactic Trans-
fusions in Patients 
on Devices (n = 77)
Prophylactic Trans-
fusions to Meet 
Threshold (n = 278) p 
PICU length of stay (d), 
median (IQR)
10 (4–27) 14 (7–27) 25 (12–50) 11.5 (5–26) < 0.001
Mechanical ventilator-free 
days, median (IQR)
2 (0–8) 3 (0–9) 2 (0–7) 5 (1–10) < 0.001
Total platelet dose (mL/kg), 
median (IQR)
30.9 (13.5–67.3) 27.3 (10.4–62.1) 97.7 (40.0–243.0) 28.6 (12.3–79.8) < 0.001
Mortality, n (%) 18 (28.1) 40 (35.4) 27 (35.1) 48 (17.3) < 0.001
IQR = interquartile range.
Of the 559 patients transfused and enrolled, 532 had reported outcome data.
TABLE 3. Multiple Logistic Regression Model of Independent Variables and ICU Mortality
Candidate Independent Variables OR (95% CI) p
Full days since PICU admission 1.021 (1.006–1.036) 0.007
Postoperative at admission 1.676 (0.940–2.990) 0.080
Extracorporeal life support 3.256 (1.782–5.951) < 0.001
Lowest platelet count at admission 0.995 (0.990–1.001) 0.089
PELOD score on day of transfusion 1.311 (1.220–1.408) < 0.001
Indication for transfusion = major or minor bleeding 2.391 (1.463–3.906) 0.001
Total administered dose of platelets 1.002 (1.001–1.003) 0.005
OR = odds ratio.
Continuous renal replacement therapy and PELOD score at admission removed from model based on likelihood ratio test in backward stepwise model.
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room temperature may be relatively inert and not consumed 
at a high enough rate to show reduced increments compared 
with nonbleeding patients. “Cold” platelets (stored at 4°C) 
have been shown to have increased hemostatic efficacy and 
increased safety relative to bacterial contamination (12–14).
Our study confirms that clinicians rely on few assays, other 
than TPC alone, to prescribe platelet transfusions. Whiting et 
al (15) suggest that viscoelastic testing is more effective than 
standard laboratory testing to guide transfusion therapy in 
adults undergoing cardiac surgery or following trauma. A 
recent Cochrane review analyzing the benefit of viscoelastic 
testing to monitor hemostatic treatment versus usual care in 
adults or children with bleeding reported that application of 
thromboelastography- or ROTEM-guided transfusion strat-
egies may reduce the need for blood products and improve 
morbidity (16). The Effects of Prophylactic Platelet Dose on 
Transfusion Outcomes (PLADO) trial, comparing different 
platelet doses in adults and children with hematologic malig-
nancies, reported a poor relationship between degree of sever-
ity of thrombocytopenia and bleeding risk (17). More work 
needs to be done to define bleeding risk, other than isolated 
platelet counts, in critically ill children.
Given there are few evidence-based guidelines for platelet 
transfusion in critically ill children, it is not surprising that sig-
nificant variation in prescribing practices exists. Randomized 
trials represent the goal for evidence-based practitioners, but 
we must recognize considerable challenges undertaking tri-
als of platelet transfusions in critically ill children. Alternative 
designs, such as comparative effectiveness methods, need to be 
considered. Since nearly half the children in this cohort had 
an underlying oncologic diagnosis, this specific population 
should be investigated. Future studies should also focus on 
children supported by circulatory devices since they receive the 
highest exposure to platelet transfusions with high mortality.
This study represents the largest prospective study of plate-
let transfusions in critically ill children reported to date. Since 
the data were predominantly collected with waiver of consent, 
it is without selection bias. Given the number of international 
sites, results should be externally valid for PICUs with platelet 
transfusions readily available in their blood banks. The results, 
although primarily descriptive in nature, provide important 
preliminary data that identify at-risk patient populations and 
will facilitate the design of future trials.
Some limitations exist. Unfortunately, there is no validated 
bleeding assessment tool in critically ill children, so it was not 
included as an outcome. Data were not collected on transfu-
sion of other hemostatic products, such as plasma, cryopre-
cipitate, or antifibrinolytics. Since we did not collect data on 
the 16,375 nontransfused patients, we cannot directly com-
pare patients transfused and not transfused. The number of 
sites that did not transfuse any subjects were limited to North 
America and Europe and may represent different regional 
approaches to platelet transfusions. Data were not collected 
on platelet transfusions ordered by anesthesiologists or sur-
geons so only reflects practices of pediatric intensivists. Data 
on adverse events related to the transfusions were collected 
passively. The population of children transfused had increased 
acuity compared with the general PICU population, in both 
median Pediatric Logistic Organ Dysfunction-2 scores (7 vs 
4) and mortality (25% vs 3%) (18). Finally, the association 
between platelet dose and mortality must be interpreted with 
caution as patients who are sicker are often more heavily trans-
fused, and this confounding cannot be removed entirely.
In conclusion, the majority of platelet transfusions pre-
scribed in the PICU are given prophylactically to nonbleed-
ing children, and significant variation in platelet thresholds 
exists. Studies are needed to clarify appropriate indications 
for platelet transfusion and subsequent responses in critically 
ill children according to their illness, with particular focus on 
prophylactic transfusions. Further work should investigate the 
association between administered platelet dose and mortality.
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